See the story behind Verzenio, a treatment option for HR+, HER2– metastatic breast cancer
Every Day Matters
For women living with HR+, HER2– metastatic breast cancer, every day matters. Learn about an everyday CDK4 & 6 inhibitor for a relentless disease.
The Relentless Story
Every story starts with an inspiration. The Verzenio story started years ago when it was first envisioned in a laboratory, inspired by women with metastatic breast cancer, and a mission to help them. They are at the heart of everything we do.
See the story behind the first everyday, twice-a-day CDK4 & 6 inhibitor for HR+, HER2– metastatic breast cancer, which was inspired by the relentless women living with this disease.
SELECT SAFETY INFORMATION
Verzenio may cause serious side effects, including:
Low white blood cell counts (neutropenia) are common with Verzenio and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment. Tell your doctor right away if you have fever or chills.